Disease · HP_0100716
Self-injurious behavior
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Self-injurious behavior. Diseases, record HP_0100716. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100716
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Self-injurious behavior
- Open Targets ID
- HP_0100716
- Other names
- Autoagression, Self injury, Self-harm, Self-injurious behaviors, Self-injurious behaviours
- Highest stage of its drugs
- Phase 3, for 6 of its 12 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TOPIRAMATE | CHEMBL220492 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CLOZAPINE | CHEMBL42 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ECOPIPAM | CHEMBL298406 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALTREXONE HYDROCHLORIDE | CHEMBL1201149 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLANZAPINE | CHEMBL715 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISPERIDONE | CHEMBL85 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BROMOCRIPTINE | CHEMBL493 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets49
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | 4 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 3 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 2 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 2 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 2 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 3 | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/762 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| DRD1 | D(1A) dopamine receptor | 1 | Dopamine D1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1812 | Drugs and targets |
1 to 10 of 49
See all 49 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01751802 | Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease | Phase 3 | 9 | 2015-10-08 | Lesch-Nyhan Disease, Self-injurious Behavior | ECOPIPAM | Its record names the disease | ClinicalTrials.gov |
| NCT03008889 | A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder | Phase 2 | 8 | 2020-12-16 | Autism Spectrum Disorder | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
| NCT00539188 | N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD | Phase 2 | 6 | 2013-03-06 | Borderline Personality Disorder, Self-Injurious Behavior | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
| NCT01929642 | Rapalogues for Autism Phenotype in TSC: A Feasibility Study | Phase 2 | 3 | 2021-03-29 | Tuberous Sclerosis Complex, Self-injury, Autism | EVEROLIMUS, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02810483 | Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks | Phase 3 | 69 | Prader-Willi Syndrome | TOPIRAMATE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00065273 | Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay | Phase 3 | 50 | Mental Retardation, Developmental Delay Disorder | CLOZAPINE, OLANZAPINE, RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT04517799 | Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism | Phase 2 | 42 | Autism, Autism Spectrum Disorder | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00004300 | Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis | Phase 2 | 40 | Stereotyped Behavior, Mental Retardation | BROMOCRIPTINE, SERTRALINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00065936 | Self-Injury: Diagnosis and Treatment | Phase 3 | 37 | Self-Injurious Behavior, Mental Retardation | NALTREXONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT07564245 | Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders. | Phase 2 | 21 | Neurodevelopmental Disorders With Severe Self-injuries | CANNABIDIOL | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ecopipam vs Placebo: serious adverse events | 2 of 9 | 1 of 6 | 15 | NCT01751802 | Trial comparisons |
| N-Acetylcysteine vs Placebo: serious adverse events | 0 of 3 | 0 of 2 | 5 | NCT00539188 | Trial comparisons |
| Participants Taking NAC vs Participants Taking Placebo: Successful Collection of Outcome Measures | 1 of 1 | 1 of 1 | 2 | NCT03008889 | Trial comparisons |
| Participants Taking NAC vs Participants Taking Placebo: Parent Satisfaction Rating | 1 of 1 | 1 of 1 | 2 | NCT03008889 | Trial comparisons |
| Participants Taking NAC vs Participants Taking Placebo: Study Medication Compliance | 1 of 1 | 1 of 1 | 2 | NCT03008889 | Trial comparisons |
| Participants Taking NAC vs Participants Taking Placebo: deaths from any cause | 0 of 1 | 0 of 1 | 2 | NCT03008889 | Trial comparisons |
| Participants Taking NAC vs Participants Taking Placebo: serious adverse events | 0 of 1 | 0 of 1 | 2 | NCT03008889 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 40410546 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100716
GET https://conductscience.org/api/diseases/v1/HP_0100716/targets?page=2